Intervention Review

Triflusal for preventing serious vascular events in people at high risk

  1. João Costa1,*,
  2. José M Ferro2,
  3. Jordi Matias-Guiu3,
  4. Jose Alvarez-Sabin4,
  5. Ferran Torres5

Editorial Group: Cochrane Stroke Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 21 FEB 2005

DOI: 10.1002/14651858.CD004296.pub2


How to Cite

Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004296. DOI: 10.1002/14651858.CD004296.pub2.

Author Information

  1. 1

    Faculdade de Medicina de Lisboa, Laboratório de Farmacologia Clínica e Terapêutica, Lisboa, Portugal

  2. 2

    Santa Maria Hospital, Department of Neurology, Lisboa, Portugal

  3. 3

    Hospital General Universitario de Alicante, Service of Neurology, Alicante, Spain

  4. 4

    Vall d'Hebron Hospital, Department of Neurology, Barcelona, Spain

  5. 5

    Universitat Autonoma de Barcelona, Laboratorio de Bioestadistica y Epidemiologia, Barcelona, Spain

*João Costa, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz, Lisboa, 1649-028, Portugal. joaoncosta@sapo.pt.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Graeme J Hankey, Secondary stroke prevention, The Lancet Neurology, 2014, 13, 2, 178

    CrossRef

  2. 2
    Maria Lukasik, Michal K. Owecki, Efficacy of Antiplatelet Treatment in Stroke Prevention: Past, Present, and Future, Drug Development Research, 2013, 74, 7
  3. 3
    Peter M Rothwell, Ale Algra, Pierre Amarenco, Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke, The Lancet, 2011, 377, 9778, 1681

    CrossRef

  4. 4
    Graeme J Hankey, John W Eikelboom, Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events, The Lancet Neurology, 2010, 9, 3, 273

    CrossRef

  5. 5
    Fernando Rigo Carratalá, Guillem Frontera Juan, Irene Sempere Flores, Silvia Tur Campos, Juan Guillaumet Castellanos, Alberto Berna, Prevención secundaria en enfermedad cardiovascular, FMC - Formación Médica Continuada en Atención Primaria, 2010, 17, 5

    CrossRef

  6. 6
    V. Riambau-Alonso, S. Fernández, M. Lara, M.D. Caballero, E. Rubio, A. Martín, Estudio epidemiológico observacional para evaluar el manejo de los trastornos gastrointestinales en el paciente con tratamiento antiagregante, Angiología, 2009, 61, 4, 185

    CrossRef

  7. 7
    J. Fraj, A. Valero, R. Vives, I. Pérez, J. Borja, I. Izquierdo, C. Picado, Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases, Allergy, 2008, 63, 1
  8. 8
    Graeme J. Hankey, Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines, Current Medical Research and Opinion, 2007, 23, 6, 1453

    CrossRef

  9. 9
    Jia Liu, Lu-Ning Wang, Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack, The Cochrane Library,
  10. 10
    Jia Liu, Lu-Ning Wang, Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack, The Cochrane Library,